Targeting Solid Tumors
Welcome to Gilboa. We are a preclinical-stage biopharmaceutical company focused on the development of novel, next-generation cancer immunotherapies designed to harness the power of a patient’s own immune system to treat cancer, improve outcomes, and save lives.
While immunotherapies have improved outcomes for some patients, unfortunately, many patients do not respond to currently available therapies. At Gilboa, our mission is to enable more patients to respond, as well as improve response rates, by applying our game-changing approach to fighting cancer.
Gilboa’s proprietary SolidT technology, originated in Dr. Yaron Carmi’s lab at Tel Aviv University. The technology is an engineered T cell therapy that is intended to be used in combination with a wide range of tumor-specific antibodies to target multiple different tumor types.
Autologous T cell therapy, genetically modified to attack tumor cells
(e.g., chimeric antigen receptors, CARs) among the most powerful tool to date in the hands of clinicians for treating cancer. Despite initial success in hematological malignancies, conventional CAR-T has demonstrated limited efficacy towards solid tumors which remain inaccessible. Dangerous side effects further limit the utility of current technologies.
Therefore, there is an urgent need to develop next-generation T cell therapy capable of eradicating solid tumors.
Gilboa Therapeutics’ breakthrough SolidT technology attacks these solid tumor cells with unprecedented safety and efficiency, bringing about complete remission in mouse models.
SolidT cell therapy is based on T cells that are genetically engineered to express a modified, high-affinity antibody receptor. This antibody receptor allows the engineered T cells to identify targets through an antibody intermediate. Tumor cells labeled by a tumor-specific antibody are then targeted for efficient killing by these T cells.
SolidT cells are designed to deliver a highly specific and potent attack that results in eradication of tumor cells, leaving healthy tissue unharmed.
SolidT killing in-vitro
Blood is collected from a patient
T cells are harvested from a patient’s blood
Genetically modified SolidT receptor is engineered into patient’s T cells followed by in vitro cell expansion
These engineered T cells are reinfused back into the patient along with tumor targeting antibodies
Gilboa has assembled a strong development team backed up by world class industry and clinical experts. Recognizing the significant, unmet medical need, we are driven by a sense of urgency to discover, develop and bring game-changing new therapeutics to cancer patients in need.
Peleg Rider, PhD
Co-inventor of Gilboa Therapeutics’ technology. Former research associate at Carmi’s lab in Tel-Aviv University, published over 20 papers in the field of Immunology and holds 3 patents.
Accomplished, US-based biotech executive with more than 30 years of leadership experience in public and private companies. Served as CEO for two clinical stage immune-oncology companies and led IPO for one.
Yaron Carmi, PhD
Co-Founder at Bolt Biotherapeutics which raised over 400M USD, professor at Tel-Aviv University, published over 35 papers and holds 5 patents.
Former manager of 400M NIS trust funds, entrepreneur, a former pilot in the Israeli air force, investor.
Shahar Dotan, PhD
A Biotechnology R&D manager with over 15 years of experience in biotech companies.
Completed her PhD studies at Carmi’s lab, co-inventor of Gilboa therapeutics technology. Has an engineering degree in biotechnology from Ben-Gurion University.
M.Sc. degree in Medical Sciences from Tel-Aviv University.
Executive Assistant to CEO & Office Manager
Executive Administrative and Operations Manager with 13 years of experience in C-Suite support and project management.
OUR SCIENTIFIC ADVISORY BOARD
Lawrence Fong, MD
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the UCSF. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer
Yaron Carmi, Chairman
Co-Founder at Bolt Biotherapeutics which raised over 400M USD, professor at Tel-Aviv University, published over 35 papers and holds 5 patents
Ezra Cohen, MD
Michal Besser, PhD
Ezra Cohen, MD, is Chief of the Division of Hematology‐Oncology, and Co‐Director of the San Diego Center for Precision Immunotherapy. A physician scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics
Michal Besser, PhD is a former laboratory director at the Ella Lemelbaum Institute for Immuno-Oncology and CSO of the Advanced Biotherapy Center GMP facility at the Sheba Medical Center